Skip to content

Application of aluminum fluoride-labeled PSMA positron imaging agent in prostate tumors

Application of aluminum fluoride-labeled PSMA positron imaging agent in prostate tumors

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053507
Enrollment
Unknown
Registered
2021-11-23
Start date
2020-09-28
Completion date
Unknown
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:Pathological results
Index test:PET/CT/MRI&#32
imaging&#32
examination&#32
of&#32
aluminum&#32
fluoride-labeled&#32

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Primary prostate cancer: (1) PSA and routine imaging examinations suggest PCa; (2) No invasive prostate examination or treatment has been performed recently; (3) When the biopsy results of the other hospital (one or more times) are negative and PCa is still highly suspected, the PET/CT/MRI examination should be performed 30 days after the puncture (to avoid the influence of the puncture site); (4) Patients who plan to undergo needle biopsy in our hospital to obtain pathological results (type, location, Gleason grade and score, etc.). 2. Patients with postoperative biochemical recurrence of prostate cancer: (1) Patients with serum PSA level >= 0.1 ng/ml after radical prostatectomy; (2) The first PET/CT/MR examination should be performed before endocrine therapy or radiotherapy; (3) Patients who plan to perform needle biopsy or surgical resection of the lesions detected by PET/MR in our hospital, and the pathological results can be obtained; (4) Patients who have completed PET/CT/MR examination and planned to undergo a second PET/CT/MRI or other imaging methods for follow-up after treatment.

Exclusion criteria

Exclusion criteria: Patients with metal implants such as pacemakers, defibrillators, hearing aids, insulin pumps, etc.

Design outcomes

Primary

MeasureTime frame
SUVmax;accuracy, specificity, sensitivity;

Countries

China

Contacts

Public ContactZhang Jinming

Chinese PLA General Hospital

zhangjm301@163.com+86 13801210291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026